Update shared on01 Aug 2025
Fair value Increased 31%The notable increase in Exagen’s consensus price target reflects improvements in profitability as evidenced by a higher net profit margin, alongside a rising future P/E, resulting in a revised fair value of $10.83 per share.
What's in the News
- Exagen expects 2025 full-year revenue between $65 million and $70 million and aims for positive adjusted EBITDA in the fourth quarter if the high end is achieved.
- Company added to Russell Microcap Index, Russell Microcap Growth Index, Russell 3000E Index, Russell 3000E Growth Index, and Russell 3000E Growth Benchmark Index.
- Completed a follow-on equity offering, raising approximately $17.6 million through the sale of 3,350,000 shares at $5.25 per share.
- Previously filed for a follow-on equity offering prior to completion.
- Reaffirmed 2025 revenue guidance of at least $65 million.
Valuation Changes
Summary of Valuation Changes for Exagen
- The Consensus Analyst Price Target has significantly risen from $8.50 to $10.83.
- The Net Profit Margin for Exagen has significantly risen from 10.54% to 12.20%.
- The Future P/E for Exagen has significantly risen from 26.83x to 30.74x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.